WO1997001576A2 - Peptides phenyles, leur procede de preparation et les compositions pharmaceutiques qui en renferment - Google Patents
Peptides phenyles, leur procede de preparation et les compositions pharmaceutiques qui en renferment Download PDFInfo
- Publication number
- WO1997001576A2 WO1997001576A2 PCT/FR1996/001008 FR9601008W WO9701576A2 WO 1997001576 A2 WO1997001576 A2 WO 1997001576A2 FR 9601008 W FR9601008 W FR 9601008W WO 9701576 A2 WO9701576 A2 WO 9701576A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ile
- amino
- leu
- sulfur
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 20
- -1 alkyl radical Chemical class 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 18
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 14
- 239000001301 oxygen Substances 0.000 claims abstract description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000005518 carboxamido group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 5
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 239000011593 sulfur Substances 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 claims description 7
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 claims description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 claims description 3
- RGKBHCHHMKMETO-UHFFFAOYSA-N sulfurous diamide Chemical compound NS(N)=O RGKBHCHHMKMETO-UHFFFAOYSA-N 0.000 claims description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 16
- 230000010076 replication Effects 0.000 abstract description 8
- 108010017640 Aspartic Acid Proteases Proteins 0.000 abstract description 5
- 102000004580 Aspartic Acid Proteases Human genes 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 108010076039 Polyproteins Proteins 0.000 abstract description 4
- 101710172711 Structural protein Proteins 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000002243 precursor Substances 0.000 abstract description 3
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 5
- LJPDJTPZNJKXPW-QMMMGPOBSA-N Tert-butyl n-[1-(aminocarbonyl)-3-methylbutyl]carbamate Chemical compound CC(C)C[C@@H](C(N)=O)NC(=O)OC(C)(C)C LJPDJTPZNJKXPW-QMMMGPOBSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 108010010369 HIV Protease Proteins 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002333 glycines Chemical class 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KFKWRHQBZQICHA-STQMWFEESA-N Leu-Phe Chemical group CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical class OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000002461 renin inhibitor Substances 0.000 description 3
- 229940086526 renin-inhibitors Drugs 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- FHCQJCPUKNPKLZ-BQBZGAKWSA-N (2S,3S)-2-amino-3-hydroxy-6-methylheptanoic acid Chemical compound N[C@H](C(=O)O)[C@H](CCC(C)C)O FHCQJCPUKNPKLZ-BQBZGAKWSA-N 0.000 description 1
- VJROPLWGFCORRM-YFKPBYRVSA-N (2s)-2-methylbutan-1-amine Chemical compound CC[C@H](C)CN VJROPLWGFCORRM-YFKPBYRVSA-N 0.000 description 1
- DNGHLMOUASDWRU-CCKIYBGTSA-N (2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropano Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)CC1=CC=CC=C1 DNGHLMOUASDWRU-CCKIYBGTSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VTQHAQXFSHDMHT-UHFFFAOYSA-N 2-amino-3-methylpentan-1-ol Chemical compound CCC(C)C(N)CO VTQHAQXFSHDMHT-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- XLMSKXASROPJNG-UHFFFAOYSA-N 2-azaniumyl-2-thiophen-2-ylacetate Chemical compound OC(=O)C(N)C1=CC=CS1 XLMSKXASROPJNG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- IYRWEQXVUNLMAY-UHFFFAOYSA-N carbonyl fluoride Chemical class FC(F)=O IYRWEQXVUNLMAY-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- LONYOMRPNGXPGP-UHFFFAOYSA-N ethene-1,1-diol Chemical group [CH2][C](O)O LONYOMRPNGXPGP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UVIZKKLXYCUTJB-UHFFFAOYSA-N prop-2-enyl 2-hydroxyacetate Chemical compound OCC(=O)OCC=C UVIZKKLXYCUTJB-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to the field of organic chemistry and more particularly to that of therapeutic chemistry.
- the invention relates to a synthetic peptide containing at least nine amino acids of formula: Ile-Arg-Lys-Ile-Phe-Leu-Asp-Gly-Ile, including the methylene group carried by the phenylalanine molecule ( Phe) has been replaced by an isostere, that is to say that the change in structure according to the invention can be written as follows:
- R is an alkyl radical, linear or branched
- R '' is an alkyl, phenyl, halogen, nitro, amino, alkyl amino, alkoxy, trifluoromethyl, trifluoromethoxy, carboxamido or cyano radical
- Z is sulfur, oxygen, amino or sulfoxide and n is 0, 1 , 2 or 3.
- Patent WO-A-91 10679 describes renin inhibitor peptides, having an amino acid with an ⁇ heteroatom at the P 3 position of the peptide of general formula:
- A represents the position P 4
- X the position P 3 / Y the position P 2 and, W and U the positions P x and P ' 3.
- A is IVA (isovaleryl) or BOC (ter-butyloxycarbonyl)
- X is -NHCH (SPh) CO-, -NHCH (OPh) CO-, -NHCH (NHPh) CO-,
- Y is HIS (L-histidine) or LEU (L-leucine)
- W is CAD (peptidylaminodiols) or STA (4 (S) -amino-3 (S) - hydroxy-6-methyl heptanoic acid)
- U is MBA (1-hydroxymethyl-2-methyl-butylamine) with the restriction that if W is CAD, U is absent
- Renin like the HIV protease, is an aspartyl protease and the compounds of patent WO-A-91 10679 are also used to treat diseases caused by retroviruses including HTLV -I, -II, -III.
- P and Q can in particular be amino acids
- the glycyl unit i is the unit carrying the chemotherapeutic residue W.
- One of the preferred compounds of the invention is L-alanyl-L- ( ⁇ -phenylthio) glycine.
- These prodrugs are used to increase penetration into infected cells, against which the transported chemotherapy residues (W) are active.
- chemotherapeutic residues for example thiophenol
- chemotherapeutic residues are antimicrobial or antiparasitic agents.
- Inhibition of renin can provide effective treatment for hypertension.
- BNMA (position P 3 ) represents acetic acid bis (1- naphthylmethyl)
- STA (position P x ) represents heptanoic acid 4 (S) -amino- 3 (S) -hydroxy-6-methyl
- MBA (position P ' x ) represents the 2 (S) -methylbutylamine X can for example be: SC 6 H 5 , 0-C 6 H 5 , NC ⁇ H 5
- the S-, O- and N-aryl derivatives are generally less active than their alkylated analogs.
- Ala represents alanine
- TPG represents thiophenylglycine (-NHCH (SPh) CO-)
- ⁇ -substituted glycine peptides are used to transport the drug into the microbial cell.
- Ar is an unsubstituted or substituted phenyl radical.
- Z is an isostere as defined above.
- Ile is the amino acid isoleucine
- Arg is the amino acid arginine
- Lys is the amino acid lysine
- Leu is the amino acid leucine
- Gly is the amino acid glycine
- Z is sulfur
- the compounds of formula I are inhibitors of HIV replication by acting as an inhibitor of a small dimeric aspartyl protease which specifically cleaves the precursors of a polyprotein encoding the structural proteins and enzymes constituting the virus (Martin SA, Recent Advances in the Design of HIV proteinase inhibitors, Antiviral Res. 17 (1992) 265-278).
- Y is a phenyl radical, unsubstituted or substituted by one, two or three substituents R ''
- Z is a sulfur, oxygen, amino and sulfur isoster
- This synthon II is prepared by the following method: Boc-Leucinamide (3) [(Boc Leu) amino] »+ allyl glyoxylate (4) allyl hydroxyacetate (5)
- Boc-Leucinamide (3) was condensed with allyl glyoxalate hydrate (4) to provide the corresponding ⁇ -hydroxylated derivative, therefore the allyl ester of Boc-Leu-Gly (5).
- the resulting ester (6) was displaced by a nucleophilic agent such as a thiophenol to obtain the compound (7).
- a nucleophilic agent such as a thiophenol
- the same type of synthesis can be used to introduce an -O- or -NH- isostere.
- the sulfur oxide compound is prepared by oxidation using a peroxide of the corresponding sulfur derivative.
- the various amino acids which constitute the chain of this peptide containing at least nine amino acids.
- Leu- (S) Phe can be represented as follows: O
- compositions intended in particular for the treatment of viral infections due to the HIV virus, which contain, as active principle, at least one compound of general formula I:
- R is a linear or branched alkyl radical
- R '' is an alkyl, phenyl, halogen, nitro, amino, alkyl amino, alkoxy, trifluoromethyl, trifluoromethoxy, carboxamido or cyano radical
- Z is sulfur, oxygen, amino or sulfoxide and n is 0, 1, 2 or 3
- compositions in particular intended for the treatment of viral infections due to the HIV virus, which contain, as active principle, at least one compound of simplified formula (I):
- Z is sulfur, oxygen, amino or sulfur oxide
- Ar is a phenyl radical, unsubstituted or substituted
- Ar preferably used as active ingredient, that for which Ar is a phenyl radical. It is also possible to use compounds for which Ar is a phenyl substituted by one, two or three radicals chosen from the group formed by a lower alkyl, a lower alkoxy, a trifluoromethyl, a trifluoromethoxy, a nitro, a carboxamido, a cyano, the halogens and phenyl.
- the AIDS virus produces a dimeric aspartyl protease which specifically cuts off the polyprotein precursors which code for the structural proteins and enzymes that make up the virus.
- proteolytic activity is necessary for the production of mature infectious virions and is, therefore, an interesting objective for a therapeutic intervention.
- Chemists in therapeutic chemistry have tried to design and synthesize inhibitors of this enzyme aspartyl protease which plays a decisive role.
- transition state analog This concept consists in synthesizing the shortest possible peptide substrate, in which the amide bond, normally cleaved, is replaced by a non-hydrolysable function mimicking a motif of the tetrahedral transition state.
- HIV1 protease inhibitors have also been designed taking into account the tertiary structure of the enzyme. These compounds can be classified as symmetric inhibitors or as dimerization inhibitors. In an effort to increase the generality and the approach of the anti-HIV peptide, the applicants made their study focus on a new concept of HIV-2 inhibitor based on the following experimental observations:
- Synthon (II) was used in the form of the mixture of diastereoisomers. Taking into account the unexpected anti-HIV results, it is advantageous to perform the separation by reverse phase HPLC of the mixture of (2) and / or the enantiomeric synthesis of the corresponding peptide in a second research step.
- the model peptides listed in Table 1 were incubated with the partially purified HIV-1 protease using a standard procedure (Billich, J. Biol. Chem. 1988, 263, 17905-17908) and the cleavage products were analyzed by reverse phase HPLC. Only the peptide 1 model was cleaved. Surprisingly, the sulfur-containing peptides (2,7,8,9,10 and 11) were resistant to any proteolytic cleavage under the conditions of the test. In addition, the sulfur-containing peptides were added to a test using peptide I as a substrate model. It was found that they were not inhibitors at concentrations of molarity equal to the substrates (approximately 2 mM).
- the evaluation of the antiviral effect is based on the study of the cytopathogenic effect of the HIV 1 virus on the MT4 cell line.
- the MT4 line originates from T cells isolated from a patient, transformed by the HTLV 1 virus. This line is mycoplasmated. Mycoplasmas are ubiquitous infectious agents, bacteria living on the surface of MT4 as natural hosts. This bacterium, of the order of 300 to 700 nm, is responsible for the great cytopathogenic effect of HIV by the formation of giant cells (fusion by gp 120) called SYNCITIA. This HIV infection is observed 4 to 5 days after infection and followed by cell death.
- This cytopathogenic effect is directly correlated with infection of cells by the virus, its intracellular replication and the expression of viral antigens by cells. An inhibition of this effect therefore corresponds to an inhibition of the multiplication of the HIV 1 virus.
- This lymphoblastoid line infected with HIV 1 can be used for viral production.
- the antiviral perspectives mainly concern the protease inhibitors which control the maturation of proteins and therefore the production of infectious particles, as well as the inhibitors of the TAT protein which participates in the awakening and dissemination of the positive regulatory virus of viral transcription. and finally on reverse transcriptase inhibitors which transform viral RNA into double stranded DNA, containing the viral message and which integrates as a provirus in the DNA of the host cell.
- Successive dilutions are made in 10% medium in order to be able to culture the MT4 for 8 days and to be able to read the formation of syncitia.
- the MT4 cells are washed 3 times with RPMI 1640 and cultured at the rate of 3.10 5 cells for 1 ml of each of the concentrations of the compounds to be tested in plates 24 wells. The day of cultivation is considered OJ.
- the MT4 cells are diluted 1/3, again in the different concentrations of the antiviral. Each day, the appearance of syncitia is observed under the microscope to see if there is a delay compared to the HIV-1 control.
- the reverse transcriptase assay is carried out. If the cells are not infected, then there has been protection by the antiviral tested. The dose IC 50 , concentration of the antiviral which inhibits by 50% the value of the reverse transcriptase of the HIV 1 control, has been determined.
- TI therapeutic index concentration required for 50% of MT4 cells to be uninfected (ID 50 ) compared to the concentration required to inhibit syncitia formation by 50% (IC 50 )
- the foreseeable dosage of the compounds of general formula I will be between 0.1 and 100 mg per unit dose.
- Their administration will be by digestive or parenteral route. Their use may be envisaged in the treatment of diseases linked to HIV viruses in the form of injectable compositions or else in the form of capsules or tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9606455A BR9606455A (pt) | 1995-06-29 | 1996-06-28 | Peptídeo sintético processo de obtenção de peptídeos composições farmacêuticas e intermediário |
AU64624/96A AU706799B2 (en) | 1995-06-29 | 1996-06-28 | Phenyl peptides, method for preparing same and pharmaceutical compositions containing said peptides |
APAP/P/1997/000964A AP683A (en) | 1995-06-29 | 1996-06-28 | Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides. |
JP9504212A JPH10505613A (ja) | 1995-06-29 | 1996-06-28 | フェニルペプチドと、その製造方法と、このペプチドを含む医薬品組成物 |
KR1019970701333A KR970705576A (ko) | 1995-06-29 | 1996-06-28 | 페닐 펩티드, 이를 제조하는 방법, 및 이 펩티드를 함유하는 약제학적 조성물(phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides) |
US08/793,647 US5844078A (en) | 1995-06-29 | 1996-06-28 | Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides |
NZ312726A NZ312726A (en) | 1995-06-29 | 1996-06-28 | Phenyl peptides; preparation; medicaments |
IL12034196A IL120341A (en) | 1995-06-29 | 1996-06-28 | Phenyl peptides their preparation and pharmaceutical compositions containing them |
EP96924035A EP0787143A2 (fr) | 1995-06-29 | 1996-06-28 | Peptides phenyles, leur procede de preparation et les compositions pharmaceutiques qui en renferment |
NO970895A NO970895L (no) | 1995-06-29 | 1997-02-27 | Fenylpeptider, fremgangsmåte for fremstilling av disse, og farmasöytiske preparater inneholdende disse peptider |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/07817 | 1995-06-29 | ||
FR9507817A FR2736055B1 (fr) | 1995-06-29 | 1995-06-29 | Nouveaux thiophenoxy peptides, leur procede de preparation et les compositions pharmaceutiques en renfermant |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997001576A2 true WO1997001576A2 (fr) | 1997-01-16 |
WO1997001576A3 WO1997001576A3 (fr) | 1997-05-15 |
Family
ID=9480502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/001008 WO1997001576A2 (fr) | 1995-06-29 | 1996-06-28 | Peptides phenyles, leur procede de preparation et les compositions pharmaceutiques qui en renferment |
Country Status (17)
Country | Link |
---|---|
US (1) | US5844078A (fr) |
EP (1) | EP0787143A2 (fr) |
JP (1) | JPH10505613A (fr) |
KR (1) | KR970705576A (fr) |
CN (1) | CN1165521A (fr) |
AP (1) | AP683A (fr) |
AU (1) | AU706799B2 (fr) |
BR (1) | BR9606455A (fr) |
CA (1) | CA2197861A1 (fr) |
FR (1) | FR2736055B1 (fr) |
HU (1) | HUP9701940A3 (fr) |
IL (1) | IL120341A (fr) |
NO (1) | NO970895L (fr) |
NZ (1) | NZ312726A (fr) |
OA (1) | OA10403A (fr) |
PL (1) | PL318880A1 (fr) |
WO (1) | WO1997001576A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001470A2 (fr) * | 1997-06-30 | 1999-01-14 | Zambon Group S.P.A. | Derives peptidomimetiques inhibiteurs suicide de la proliferation du vih |
WO2000006419A1 (fr) | 1998-07-31 | 2000-02-10 | Federal-Mogul Corporation | Module de lampe au neon sans electrode pour systemes d'eclairage de vehicule |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8886480B2 (en) | 2011-06-27 | 2014-11-11 | Synaptics Incorporated | System and method for signaling in gradient sensor devices |
US9188675B2 (en) | 2012-03-23 | 2015-11-17 | Synaptics Incorporated | System and method for sensing multiple input objects with gradient sensor devices |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0094815A2 (fr) * | 1982-05-18 | 1983-11-23 | Smithkline Beckman Corporation | Oligopeptides prémédicamenteux |
US4454065A (en) * | 1982-05-18 | 1984-06-12 | Smithkline Beckman Corporation | Oligopeptide prodrugs |
EP0331921A1 (fr) * | 1988-02-11 | 1989-09-13 | Warner-Lambert Company | Inhibiteurs de la rénine, contenant des alpha-hétéroatome-acides aminés |
WO1991010679A2 (fr) * | 1990-01-22 | 1991-07-25 | Warner Lambert Co | PEPTIDES INHIBANT LA RENINE, PRESENTANT UN ACIDE AMINE A 'alpha'-HETEROATOMES EN POSITION P3 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1193598A (fr) * | 1982-05-06 | 1985-09-17 | Rafael Foguet | Derives d'acide 2-amino-benzoique et methode de preparation |
-
1995
- 1995-06-29 FR FR9507817A patent/FR2736055B1/fr not_active Expired - Lifetime
-
1996
- 1996-06-28 BR BR9606455A patent/BR9606455A/pt not_active Application Discontinuation
- 1996-06-28 CA CA002197861A patent/CA2197861A1/fr not_active Abandoned
- 1996-06-28 EP EP96924035A patent/EP0787143A2/fr not_active Withdrawn
- 1996-06-28 IL IL12034196A patent/IL120341A/xx active IP Right Grant
- 1996-06-28 US US08/793,647 patent/US5844078A/en not_active Expired - Fee Related
- 1996-06-28 HU HU9701940A patent/HUP9701940A3/hu unknown
- 1996-06-28 PL PL96318880A patent/PL318880A1/xx unknown
- 1996-06-28 WO PCT/FR1996/001008 patent/WO1997001576A2/fr not_active Application Discontinuation
- 1996-06-28 AU AU64624/96A patent/AU706799B2/en not_active Ceased
- 1996-06-28 KR KR1019970701333A patent/KR970705576A/ko not_active Application Discontinuation
- 1996-06-28 AP APAP/P/1997/000964A patent/AP683A/en active
- 1996-06-28 NZ NZ312726A patent/NZ312726A/en unknown
- 1996-06-28 JP JP9504212A patent/JPH10505613A/ja active Pending
- 1996-06-28 CN CN96190943A patent/CN1165521A/zh active Pending
-
1997
- 1997-02-27 NO NO970895A patent/NO970895L/no not_active Application Discontinuation
- 1997-02-28 OA OA60971A patent/OA10403A/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0094815A2 (fr) * | 1982-05-18 | 1983-11-23 | Smithkline Beckman Corporation | Oligopeptides prémédicamenteux |
US4454065A (en) * | 1982-05-18 | 1984-06-12 | Smithkline Beckman Corporation | Oligopeptide prodrugs |
EP0331921A1 (fr) * | 1988-02-11 | 1989-09-13 | Warner-Lambert Company | Inhibiteurs de la rénine, contenant des alpha-hétéroatome-acides aminés |
WO1991010679A2 (fr) * | 1990-01-22 | 1991-07-25 | Warner Lambert Co | PEPTIDES INHIBANT LA RENINE, PRESENTANT UN ACIDE AMINE A 'alpha'-HETEROATOMES EN POSITION P3 |
Non-Patent Citations (4)
Title |
---|
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 6, 1996, pages 609-614, XP000647604 V. NIDDAM ET AL.: "Thiophenoxy Peptides: A New Class of HIV Replication Inhibitors" * |
EUR. J. MED. CHEM. (1992), 27(1), 19-26 CODEN: EJMCA5;ISSN: 0223-5234, XP000647634 KRAUS, J. L. ET AL: "Synthesis and biological activities of new N-formylated methionyl peptides containing an.alpha.-substituted glycine residue" * |
INT. J. PEPT. PROTEIN RES. (1986), 27(6), 659-65 CODEN: IJPPC3;ISSN: 0367-8377, XP000565713 KINGSBURY, WILLIAM D. ET AL: "Synthesis of.alpha.-thiophenylglycine peptides. Novel peptide substrates useful in the study of microbial peptide transport" * |
J. MED. CHEM. (1992), 35(6), 1032-42 CODEN: JMCMAR;ISSN: 0022-2623, XP002027957 REPINE, JOSEPH T. ET AL: "Renin inhibitors containing.alpha.-heteroatom amino acids as P2 residues" * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001470A2 (fr) * | 1997-06-30 | 1999-01-14 | Zambon Group S.P.A. | Derives peptidomimetiques inhibiteurs suicide de la proliferation du vih |
WO1999001470A3 (fr) * | 1997-06-30 | 1999-03-25 | Zambon Spa | Derives peptidomimetiques inhibiteurs suicide de la proliferation du vih |
WO2000006419A1 (fr) | 1998-07-31 | 2000-02-10 | Federal-Mogul Corporation | Module de lampe au neon sans electrode pour systemes d'eclairage de vehicule |
Also Published As
Publication number | Publication date |
---|---|
NO970895D0 (no) | 1997-02-27 |
FR2736055A1 (fr) | 1997-01-03 |
AU6462496A (en) | 1997-01-30 |
EP0787143A2 (fr) | 1997-08-06 |
IL120341A0 (en) | 1997-06-10 |
IL120341A (en) | 2001-01-28 |
WO1997001576A3 (fr) | 1997-05-15 |
BR9606455A (pt) | 1998-07-14 |
NZ312726A (en) | 1998-07-28 |
US5844078A (en) | 1998-12-01 |
HUP9701940A3 (en) | 2001-07-30 |
FR2736055B1 (fr) | 1997-09-12 |
AP683A (en) | 1998-09-30 |
CA2197861A1 (fr) | 1997-01-16 |
JPH10505613A (ja) | 1998-06-02 |
CN1165521A (zh) | 1997-11-19 |
NO970895L (no) | 1997-02-27 |
AP9700964A0 (en) | 1997-04-30 |
PL318880A1 (en) | 1997-07-07 |
AU706799B2 (en) | 1999-06-24 |
OA10403A (fr) | 2001-12-05 |
KR970705576A (ko) | 1997-10-09 |
HUP9701940A2 (hu) | 1998-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meek | Inhibitors of HIV-1 protease | |
Tomasselli et al. | Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus | |
Abdel-Rahman et al. | HIV protease inhibitors: peptidomimetic drugs and future perspectives | |
CA2188470A1 (fr) | Multirepresentation d'un analogue peptidique du substrat de la dppiv, notamment de type kpr, afin d'inhiber l'entree du hiv dans les cellules | |
JPH02117615A (ja) | Hivプロテアーゼの阻害によるエイズの治療に有用なレニン阻害剤 | |
JPH0565230A (ja) | レトロウイルスプロテアーゼ阻害剤 | |
WO1997001576A2 (fr) | Peptides phenyles, leur procede de preparation et les compositions pharmaceutiques qui en renferment | |
EP0506769B1 (fr) | Composition pharmaceutique destinee au traitement ou a la prevention des infections retrovirales | |
JP2001525315A (ja) | 新規メタロプロテアーゼ阻害剤、その治療的利用およびその合成における開始化合物の製造方法 | |
EP0443573A2 (fr) | Inhibiteurs d'HIV-protéase contenant aminoacides dérivés | |
NZ237184A (en) | Hiv protease inhibitors | |
RU2238950C2 (ru) | Производные гемина и их фармацевтически приемлемые соли, способ получения, применение и фармацевтическая композиция | |
US6362165B1 (en) | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | |
Weber et al. | Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds | |
KR950703357A (ko) | 레트로바이러스 감염의 억제방법(inhibtion of retrovirus infection) | |
JPH0952900A (ja) | 亜鉛エンドペプチダーゼ24−15阻害剤として使用可能な新規ペプチド誘導体 | |
MXPA97001482A (es) | Peptidos fenilos, su procedimiento de preparaciony las composiciones farmaceuticas que loscontienen | |
CA2115972A1 (fr) | Derives cyclopeptidiques de l'angiopeptine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2968663A1 (fr) | Peptides et medicament antiviral | |
Niddam et al. | Thiophenoxy peptides: a new class of HIV replication inhibitors | |
FR2646353A1 (fr) | Utili sation de peptides contenant de la statine pour la preparation de medicaments utiles pour le traitement des maladies virales | |
FR2710917A1 (fr) | Nouveaux dérivés de peptides thérapeutiquement actifs dans la cascade de coagulation sanguine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
EP4225295A1 (fr) | Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique | |
JP2024508579A (ja) | 環状テトラペプチドおよびそれらの金属錯体 | |
KR0178575B1 (ko) | 항바이러스 활성을 갖는 펩티드 모방체 화합물 및 이를 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96190943.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN CZ HU IL JP KR MX NO NZ PL RO RU SK US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 312726 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2197861 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996924035 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08793647 Country of ref document: US Ref document number: 1199700148 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/001482 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970701333 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996924035 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970701333 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970701333 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996924035 Country of ref document: EP |